Merck Strengthens Executive Board

PR57943

DARMSTADT, Germany, Sep. 19 /PRN=KYODO JBN/ --

    Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive

Board    

    Belen Garijo appointed new member of the Executive Board   

    Changes effective from January 1, 2015   

    Merck today announced that the Board of Partners has promoted Stefan

Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive

Board. Concurrently, Belen Garijo (54) was appointed to the Executive Board to

take over leadership for the Pharma business. The management changes will

become effective as of January 1, 2015.

     (Photo: http://photos.prnewswire.com/prnh/20140924/706485-a )

     (Photo: http://photos.prnewswire.com/prnh/20140924/706485-b )

    Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman

of the Executive Board. Both will share strategic management functions and will

represent the company with politicians and international organizations.

    As a member of the Executive Board, Garijo, currently CEO of Merck's

biopharmaceutical division Merck Serono, will take on responsibility for the

whole Pharma business. Besides Merck Serono, this includes Consumer Health,

Allergy and Biosimilars.

    "With today's management decisions we strengthen Merck's leadership team

and prepare the ground for continuity to reach our ambitious growth targets

until the year 2018 and beyond," said Johannes Baillou, Chairman of the Board

of Partners of E. Merck KG. "Stefan Oschmann who has successfully reorganized

our pharma businesses over the past years will familiarize himself with

Group-wide functions and will increasingly assume external responsibilities for

the company. Belen Garijo has many years of experience in the pharma industry,

has proven that she can further develop our business organization and in her

future role will provide a significant contribution to ensure the sustainable

success of our pharma businesses."

    Note to editors

    You find pictures and CVs here.

    All Merck Press Releases are distributed by e-mail at the same time they

become available on the Merck Website. Please go to

http://www.merckgroup.com/subscribe to register online, change your selection

or discontinue this service.

    Merck is a leading company for innovative and top-quality high-tech

products in the pharmaceutical and chemical sectors. With its four divisions

Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck

generated total revenues of EURO 11.1 billion in 2013. Around 39,000 Merck

employees work in 66 countries to improve the quality of life for patients, to

further the success of our customers and to help meet global challenges. Merck

is the world's oldest pharmaceutical and chemical company - since 1668, the

company has stood for innovation, business success and responsible

entrepreneurship. Holding an approximately 70% interest, the founding family

remains the majority owner of the company to this day. Merck, Darmstadt,

Germany is holding the global rights to the Merck name and brand. The only

exceptions are Canada and the United States, where the company is known as EMD.

    SOURCE: Merck